Eccogene Announces Completed First-in-human of ECC0509 in Phase 1a Clinical Trial in Australia

by Admin | Jul 28, 2021 | Portfolio News

SHANGHAI, July 28, 2021 /PRNewswire/ — Eccogene, Inc., a clinical stage biopharmaceutical company focused on discovery and development of metabolic and immunologic therapeutics, announced the initiation of a Phase 1a clinical trial evaluating ECC0509, an oral...

Imperative Care Raises $260 Million to Advance Innovations that Elevate Stroke Care

by Admin | Jul 16, 2021 | Portfolio News

Imperative Care to Create Strategic Network of Wholly Owned Development Subsidiaries in Areas of Synergy, Starting with Acquisition of Truvic Medical, Inc., a Peripheral Thrombectomy Innovator July 15, 2021 08:00 AM Eastern Daylight Time CAMPBELL,...

Clover Biopharmaceuticals Completes Enrollment of Adult and Elderly Population in SPECTRA Global Phase 2/3 Clinical Trial for its COVID-19 Vaccine Candidate

by Admin | Jul 7, 2021 | Portfolio News

SPECTRA enrolled over 29,000 adult and elderly participants across four continents achieving high ethnic diversity and robust dataset of circulating strainsRelease of vaccine efficacy data anticipated in Q3 2021 and will include sequencing data of SARS-CoV-2 variants...

Arbutus Biopharma and Antios Therapeutics Announce Clinical Collaboration Agreement to Evaluate AB-729 in Combination with ATI-2173 in Subjects with Chronic Hepatitis B Virus Infection

by Admin | Jun 30, 2021 | Portfolio News

MENDHAM, N.J. and WARMINSTER, Pa., – Antios Therapeutics, Inc. and Arbutus Biopharma Corporation (Nasdaq: ABUS) today announced that the companies have entered into a clinical collaboration agreement to evaluate a triple combination of Arbutus’ proprietary GalNAc...

Clover Announces Advance Purchase Agreement with Gavi for Over 400 Million Doses of Clover’s COVID-19 Vaccine for the COVAX Facility

by Admin | Jun 30, 2021 | Portfolio News

Pending WHO EUL for its COVID-19 vaccine candidate, Clover is committed to providing 64 million doses in 2021 and Gavi has options for an additional 350 million doses in 2022Clover will receive a significant upfront payment, a payment upon positive Phase 2/3 data,...